Investor Presentaiton
Investor presentation
Full year 2018
Slide 121
Enhancing access to affordable medicines is a key priority
Product quality and patient safety is material
29.2 million
patients reached
with diabetes care
products
5 million people
with diabetes
treated at cost
below USD 0.16
per day
Access to insulin commitment expanded
Novo Nordisk guarantees to make low-priced human insulin
available in the world's least developed
and low-income countries, selected middle-income countries
and selected humanitarian relief organisations
103 million DKK
donations to
World Diabetes
Foundation and
Novo Nordisk
Haemophilia
Foundation
3 product recalls
O failed
inspections
78 countries,
home of
124 million
people with
diabetes
2018/2019
maximum price
4 USD/vial
0.3 million¹
people treated
at USD 0.12 per day
in average
Note: Full social statements to be found in Novo Nordisk Annual Report 2018
changing
diabetes®
1 This reflects the people covered by the 'Access to insulin commitment'.
novo nordiskView entire presentation